GEMP Gemphire Therapeutics Inc gains 21% Feb 2, 2018

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease. Its product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. The company was founded in 2008 and is headquartered in Northville, Michigan. http://www.priceseries.com/trade/GEMP-Gemphire-Therapeutics-Inc-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2018011820180202.html